http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0219308-A3
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-10 |
| filingDate | 1986-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1987-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0219308-A3 |
| titleOfInvention | 2-substituted quinolines |
| abstract | Novel compounds have the formula: <CHEM> or are pharmaceutically acceptable salts thereof. In the formula: Y is -(CR<2>=CR<2>)n-, -(C IDENTICAL C)n-, -CR<2>R<2>-X-, -X-CR<2>R<2>-, -CR<2>R<2>-X-CR<2>R<2>-, <CHEM> X, C=O, -NR<2>- @-, or -@-NR<2>-; R<1> is H, halogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, -CF3, -OR<2>, -SR<2>, -SOR<2>, -SO2R<2>, -NR<2>R<2>, -CHO, -COOR<2>, -(C=O)R<2>, -C(OH)R<2>R<2>, -CN, -NO2, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, or substituted or unsubstituted phenethyl; R<2> is H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, -CF3, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, or substituted or unsubstituted phenethyl; R<3> is -(A)m-(CR<6>=CR<6>)p-(CR<2>R<4>)m-Q; R<4> is H, halogen, -NO2, -CN, -OR<2>, -SR<2>, NR<2>R<2>, or C1-8 alkyl; R<5> is <CHEM> R<6> is H or C1-4 alkyl; R<7> is A) a monocyclic or bicyclic heterocyclic radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 nuclear heteroatoms from N, S or O, each ring in the hererocyclic radical being formed of 5 or 6 atoms, or B) the radical W-R<8>; R<8> contains up to 21 carbon atoms and is (1) a hydrocarbon radical or (2) an acyl radical of an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom in the ring; R<9> is -OR<1><0>, -SR<1><0>, or NR<1><0>R<1><0>; R<1><0> is H, C1-6 alkyl, -(C=O)R<1><1>, unsubstituted phenyl or unsubstituted benzyl; R<1><1> is H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, -CF3, or unsubstituted phenyl, benzyl, or phenethyl; R<1><2> is R<2> or halogen; m is 0-8; n is 1 or 2; p is 0 or 1; s is 0-3; A is -CR<4>R<4>-, or =C=O; Q is -COOR<2>, tetrazole, -COOR<5>, -CONHSO2R<1><1>, -CN, -CONR<1><0>R<1><0>, -NHSO2R<1><1> (but only when the sum of m, m and P in R<3> is greater than 0); or if Q is COOH and R<3> contains an R<4> which is -OH, -SH, or -NHR<2> then Q and R<4> and the carbons through which they are attached may form a heterocyclic ring with loss of water; w is O, S, or NH; and X is O, S, -SO, -SO2, or -NR<2>. The compounds are antagonists of leukotrienes and inhibitors of their biosynthesis and are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. |
| priorityDate | 1985-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.